Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder

Brian K. McNeil, Maximiliano Sorbellini, Robert L. Grubb, Andrea B. Apolo, Fabiola Cecchi, Gagani Athauda, Benjamin Cohen, Alessio Giubellino, Haley Simpson, Piyush K. Agarwal, Jonathan Coleman, Robert H. Getzenberg, George J. Netto, Joanna Shih, W. Marston Linehan, Peter A. Pinto, Donald P. Bottaro

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background: Among genitourinary malignancies, bladder cancer (BCa) ranks second in both prevalence and cause of death. Biomarkers of BCa for diagnosis, prognosis and disease surveillance could potentially help prevent progression, improve survival rates and reduce health care costs. Among several oncogenic signaling pathways implicated in BCa progression is that of hepatocyte growth factor (HGF) and its cell surface receptor, Met, now targeted by 25 experimental anti-cancer agents in human clinical trials. The involvement of this pathway in several cancers is likely to preclude the use of urinary soluble Met (sMet), which has been correlated with malignancy, for initial BCa screening. However, its potential utility as an aid to disease surveillance and to identify patients likely to benefit from HGF/Met-targeted therapies provide the rationale for this preliminary retrospective study comparing sMet levels between benign conditions and primary BCa, and in BCa cases, between different disease stages. Methods: Normally voided urine samples were collected from patients with BCa (Total: 183; pTa: 55, pTis: 62, pT1: 24, pT2: 42) and without BCa (Total: 83) on tissue-procurement protocols at three institutions and sMet was measured and normalized to urinary creatinine. Normalized sMet values grouped by pathologic stage were compared using non-parametric tests for correlation and significant difference. ROC analyses were used to derive classification models for patients with or without BCa and patients with or without muscle-invasive BCa (MIBCa or NMIBCa). Results: Urinary sMet levels accurately distinguished patients with BCa from those without (p < 0.0001, area under the curve (AUC): 0.7008) with limited sensitivity (61%) and moderate specificity (76%), and patients with MIBCa (n = 42) from those with NMIBCa (n = 141; p < 0.0001, AUC: 0.8002) with moderate sensitivity and specificity (76% and 77%, respectively) and low false negative rate (8%). Conclusions: Urinary sMet levels distinguish patients with BCa from those without, and patients with or without MIBCa, suggesting the potential utility of urinary sMet as a BCa biomarker for surveillance following initial treatment. Further studies are warranted to determine its potential value for prognosis in advanced disease, predicting treatment response, or identifying patients likely to benefit from Met-targeted therapies.

Original languageEnglish (US)
Article number199
JournalJournal of Translational Medicine
Volume12
Issue number1
DOIs
StatePublished - Oct 21 2014

Bibliographical note

Funding Information:
This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Keywords

  • Biomarker
  • Bladder cancer
  • HGF receptor
  • Met
  • Urine
  • Urothelial carcinoma

Fingerprint Dive into the research topics of 'Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder'. Together they form a unique fingerprint.

Cite this